Patents by Inventor Wolfgang Guba

Wolfgang Guba has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOUNDS
    Publication number: 20240132471
    Abstract: The invention relates to novel compounds having the general formula Ib wherein R1, R2, R1, R4, R5 and Z are as described herein, composition including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 30, 2023
    Publication date: April 25, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Lea Aurelie BOUCHE, Wolfgang GUBA, Georg JAESCHKE, Stefanie Katharina MESCH, Angélique PATINY-ADAM, Christian SCHNIDER, Sandra STEINER, Andreas Michael TOSSTORFF
  • PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES
    Publication number: 20240025883
    Abstract: Compounds having the general formula I wherein R1, R2, R3, R4, X1 and X2 are as described herein, composition including the compounds and methods of using the compounds for treatment of GPR17-mediated diseases.
    Type: Application
    Filed: August 24, 2023
    Publication date: January 25, 2024
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Luca GOBBI, Wolfgang GUBA, Dmitry MAZUNIN, Emmanuel PINARD, Antonio RICCI
  • CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES
    Publication number: 20230374014
    Abstract: The invention relates to a compound of formula (I), wherein R1-R3 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: May 18, 2021
    Publication date: November 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Katrin GROEBKE ZBINDEN, Wolfgang GUBA, Daniel HUNZIKER
  • Benzimidazole derivatives
    Publication number: 20230348398
    Abstract: The invention relates to a compound of formula (I) wherein R1-R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 14, 2021
    Publication date: November 2, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Katrin GROEBKE ZBINDEN, Daniel HUNZIKER, Wolfgang GUBA, Stefan BERCHTOLD, Danny KRUMM, Daniela KRUMMENACHER, Manuel HILBERT
  • MALONITRILE DERIVATIVES
    Publication number: 20230242494
    Abstract: The invention relates to a compound of formula (I) wherein R1-R4 and A1-A2 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: May 18, 2021
    Publication date: August 3, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guillaume DÉCORET, Guido GALLEY, Katrin GROEBKE ZBINDEN, Nicole GROSSMANN, Wolfgang GUBA, Daniel HUNZIKER
  • MALONITRILE DERIVATIVES
    Publication number: 20230242520
    Abstract: The invention relates to a compound of formula (I) wherein R1-R2 are as defined in the description and in the claims The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: May 18, 2021
    Publication date: August 3, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guillaume DÉCORET, Guido GALLEY, Katrin GROEBKE ZBINDEN, Wolfgang GUBA, Daniel HUNZIKER
  • IMIDAZOLE-PYRAZOLE DERIVATIVES AS ANTIBACTERIALS
    Publication number: 20230234939
    Abstract: The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1-R7 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: February 27, 2023
    Publication date: July 27, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Sandra Marie Joseph GRALL-ULSEMER, Wolfgang GUBA, Christian LERNER, Mingming LI, Yongqiang LIU, Markus RUDOLPH, Sébastien SCHMITT, Lorenz URNER, Yongguang WANG, Min WANG, Jianhua WANG, Song YANG, Chengang ZHOU, Patrizio MATTEI
  • Benzimidazole Derivatives
    Publication number: 20230227411
    Abstract: The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 14, 2021
    Publication date: July 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Katrin GROEBKE ZBINDEN, Daniel HUNZIKER, Wolfgang GUBA, Danny KRUMM, Daniela KRUMMENACHER, Manuel HILBERT
  • Sulfamoylamide Derivatives
    Publication number: 20230219913
    Abstract: The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 14, 2021
    Publication date: July 13, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan BERCHTOLD, Guido GALLEY, Katrin GROEBKE ZBINDEN, Wolfgang GUBA, Danny KRUMM
  • Indazole Derivatives
    Publication number: 20230192623
    Abstract: The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 14, 2021
    Publication date: June 22, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan BERCHTOLD, Guido GALLEY, Katrin GROEBKE ZBINDEN, Wolfgang GUBA, Daniel HUNZIKER, Daniela KRUMMENACHER
  • Biphenyl Derivatives
    Publication number: 20230192631
    Abstract: The invention relates to a compound of formula (I) wherein R1—R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 14, 2021
    Publication date: June 22, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan BERCHTOLD, Guido GALLEY, Katrin GROEBKE ZBINDEN, Wolfgang GUBA, Daniel HUNZIKER, Danny KRUMM
  • Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists
    Patent number: 11655243
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1-R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: May 23, 2023
    Assignees: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Kenneth Atz, Luca Gobbi, Uwe Grether, Wolfgang Guba, Julian Kretz
  • ETHYNYL DERIVATIVES
    Publication number: 20210269452
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Application
    Filed: May 9, 2021
    Publication date: September 2, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • Ethynyl derivatives
    Patent number: 11034699
    Abstract: The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 15, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Barbara Biemans, Wolfgang Guba, Georg Jaeschke, Lothar Lindemann, Fionn O'Hara, Antonio Ricci, Daniel Rueher, Eric Vieira
  • BACE1 inhibitors
    Patent number: 11034687
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: June 15, 2021
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
  • PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS
    Publication number: 20210115027
    Abstract: The invention relates to a compound of formula (I) wherein A1, A2 and R1-R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 22, 2021
    Applicants: HOFFMANN-LA ROCHE INC., EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
    Inventors: Simon M. Ametamey, Kenneth Atz, Luca Gobbi, Uwe Grether, Wolfgang Guba, Julian Kretz
  • Pyridyl-triazabicycles
    Patent number: 10829500
    Abstract: The present invention provides a compound of formula I having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: November 10, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Andreas Kuglstatter, Ulrike Obst Sander, Jens-Uwe Peters, Mark Rogers-Evans, Thomas Woltering, Christian Schnider, Roger Wermuth
  • BACE1 INHIBITORS
    Publication number: 20200308166
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 1, 2020
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
  • BACE1 inhibitors
    Patent number: 10723729
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: July 28, 2020
    Assignee: Hoffmann-Le Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Jens-Uwe Peters, Thomas Woltering
  • BACE1 inhibitors
    Patent number: 10696691
    Abstract: The present invention provides a compound of formula I, having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: June 30, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Bjoern Bartels, Cosimo Dolente, Wolfgang Guba, Wolfgang Haap, Ulrike Obst Sander, Walter Vifian, Thomas Woltering